MRL Editorial:
After 15 plus years of research and exhaustive massaging of the clinical data and spending almost billion dollars, this dog is finally put to RIP.
Guess what, the FDA review board was absolutely correct in rejecting this drug when Peter Kim presented and now, Roger Perlmutter did no better in resurrecting this dog of a product which ought to have been put to rest during the phase 2 safety assessment. Bottom line the CAT K was not a clean target which Merck knew for 10 years. Took short cuts to avoid showing of real world target risks and got tripped up in its own internal stupidity and arrogance.
It must be pointed out that this research path sounds similar to what happened with VIOXX and ARCOXIA.
"While the drug, odanacatib, reduces the risk of osteoporotic fractures, the increased risk of stroke in a late-stage study in postmenopausal women does not support further development or regulatory approval, the company said on Friday".
Lesson learned....become expert at repeating failures.
After 15 plus years of research and exhaustive massaging of the clinical data and spending almost billion dollars, this dog is finally put to RIP.
Guess what, the FDA review board was absolutely correct in rejecting this drug when Peter Kim presented and now, Roger Perlmutter did no better in resurrecting this dog of a product which ought to have been put to rest during the phase 2 safety assessment. Bottom line the CAT K was not a clean target which Merck knew for 10 years. Took short cuts to avoid showing of real world target risks and got tripped up in its own internal stupidity and arrogance.
It must be pointed out that this research path sounds similar to what happened with VIOXX and ARCOXIA.
"While the drug, odanacatib, reduces the risk of osteoporotic fractures, the increased risk of stroke in a late-stage study in postmenopausal women does not support further development or regulatory approval, the company said on Friday".
Lesson learned....become expert at repeating failures.